ArticleAIDS research and therapy2025
COVID-19-related ARDS in a young infant with uncontrolled HIV after delay in EID.
Article in AIDS research and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-19 has shown to cause generally mild disease in healthy children and adolescents. However, pediatric patients with primary immunodeficiency may develop severe and even fatal disease due to COVID-19. CASE PRESENTATION: We report the case of COVID-19-related acute respiratory failure in a 3.5-month-old infant with the diagnosis of vertical HIV transmission at disease presentation during the COVID-19 pandemic. The mother had received antiretroviral therapy from the third trimester of pregnancy and the infant had received dual neonatal prophylaxis. The first two postnatal HIV-RNA screenings immediately after birth and at the age of seven weeks were negative in this infant and follow-up screening had been planned at the age of 4 months.
conclusionsWith the description of the disease presentation and clinical course, we intend to underscore awareness regarding the possibility of delayed diagnosis of vertical HIV transmission after previous antiretroviral drug exposure. We also demonstrate the delay in prevention of vertical transmission due to COVID-19 related pandemic barriers, which underscores the need for continuation of preventive services under all circumstances. Furthermore, this is the first pediatric report describing severe COVID-19 associated morbidity during immunocompromise caused by HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.